Marburg vaccine - Hawaii Biotech/Soligenix/University of Hawaii
Alternative Names: Marburg vaccine-Soligenix; MarVax™Latest Information Update: 02 May 2024
At a glance
- Originator Soligenix
- Developer Soligenix; University of Hawaii
- Class Subunit vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Marburg virus disease
Most Recent Events
- 25 Apr 2024 Soligenix receives notice of intent to grant additional patents based on its patent compositions and methods of manufacturing trivalent filovirus vaccines in the United Kingdom and South Africa, with other international jurisdictions pending
- 15 Apr 2024 Marburg vaccine - Hawaii Biotech/Soligenix/University of Hawaii receives Orphan Drug status for Marburg virus disease (Prevention) in USA
- 03 Nov 2022 Soligenix intends to submit IND for Marburg virus disease in first half of 2023